In a phase II, single-cohort study, pediatric patients with CD19+ relapsed or refractory B-ALL treated with tisagenlecleucel had an overall survival of 90% at 6 months and 76% at 12 months [38]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.